1286 related articles for article (PubMed ID: 29343286)
21. Coexistence of familial transthyretin amyloidosis ATTR Val30Met and spinocerebellar ataxia type 1 in a Japanese family--a follow-up autopsy report.
Oide T; Arima K; Yamazaki M; Hanyu N; Ikeda S
Amyloid; 2004 Sep; 11(3):191-9. PubMed ID: 15523922
[TBL] [Abstract][Full Text] [Related]
22. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey.
Durmuş-Tekçe H; Matur Z; Mert Atmaca M; Poda M; Çakar A; Hıdır Ulaş Ü; Oflazer-Serdaroğlu P; Deymeer F; Parman YG
Neuromuscul Disord; 2016 Jul; 26(7):441-6. PubMed ID: 27238058
[TBL] [Abstract][Full Text] [Related]
23. FAP neuropathy and emerging treatments.
Adams D; Théaudin M; Cauquil C; Algalarrondo V; Slama M
Curr Neurol Neurosci Rep; 2014 Mar; 14(3):435. PubMed ID: 24482069
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area.
Takahashi R; Ono K; Shibata S; Nakamura K; Komatsu J; Ikeda Y; Ikeda T; Samuraki M; Sakai K; Iwasa K; Kayano D; Yamada M
J Neurol Sci; 2014 Oct; 345(1-2):231-5. PubMed ID: 25060417
[TBL] [Abstract][Full Text] [Related]
25. [Familial amyloid polyneuropathy: clinicopathological aspects].
Koike H; Sobue G
Brain Nerve; 2014 Jul; 66(7):749-62. PubMed ID: 24998820
[TBL] [Abstract][Full Text] [Related]
26. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy.
Coelho T; Inês M; Conceição I; Soares M; de Carvalho M; Costa J
Neurology; 2018 Nov; 91(21):e1999-e2009. PubMed ID: 30333157
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis.
Koike H; Hashimoto R; Tomita M; Kawagashira Y; Iijima M; Tanaka F; Sobue G
Amyloid; 2011 Jun; 18(2):53-62. PubMed ID: 21463231
[TBL] [Abstract][Full Text] [Related]
28. Familial amyloid polyneuropathy.
Planté-Bordeneuve V; Said G
Lancet Neurol; 2011 Dec; 10(12):1086-97. PubMed ID: 22094129
[TBL] [Abstract][Full Text] [Related]
29. Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS).
Cruz MW; Pinto MV; Pinto LF; Gervais R; Dias M; Perez C; Mundayat R; Ong ML; Pedrosa RC; Foguel D
Arq Neuropsiquiatr; 2019 Feb; 77(2):96-100. PubMed ID: 30810593
[TBL] [Abstract][Full Text] [Related]
30. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in transthyretin amyloidosis therapy.
Ueda M; Ando Y
Transl Neurodegener; 2014; 3():19. PubMed ID: 25228988
[TBL] [Abstract][Full Text] [Related]
32. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
33. A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation.
Ando Y; Terazaki H; Nakamura M; Ando E; Haraoka K; Yamashita T; Ueda M; Okabe H; Sasaki Y; Tanihara H; Uchino M; Inomata Y
Transplantation; 2004 Feb; 77(3):345-9. PubMed ID: 14966406
[TBL] [Abstract][Full Text] [Related]
34. [Current approaches for treatment of hereditary transthyretin amyloidosis (ATTR)].
Zibert A; Hüsing-Kabar A; Schmidt H
Dtsch Med Wochenschr; 2019 Oct; 144(20):1438-1443. PubMed ID: 31594020
[TBL] [Abstract][Full Text] [Related]
35. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition.
Suhr OB; Lundgren E; Westermark P
J Intern Med; 2017 Apr; 281(4):337-347. PubMed ID: 28093848
[TBL] [Abstract][Full Text] [Related]
36. An Isolated Case of Late-onset Amyloidogenic Transthyretin Type Familial Amyloid Polyneuropathy Associated with a Mutant Transthyretin Substituting Methionine for Valine at Position 30 Showing Latent Progressive Cardiac Involvement Confirmed by Serial Annual Electrocardiograms.
Sato C; Takaya T; Mori S; Hasegawa K; Soga F; Tanaka H; Watanabe Y; Nishii T; Kono AK; Morinaga Y; Ishibashi-Ueda H; Hirata KI
Intern Med; 2017; 56(2):163-168. PubMed ID: 28090046
[TBL] [Abstract][Full Text] [Related]
37. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity.
Ikeda S; Nakazato M; Ando Y; Sobue G
Neurology; 2002 Apr; 58(7):1001-7. PubMed ID: 11940682
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm.
Inomata T; Tahara N; Nakamura K; Endo J; Ueda M; Ishii T; Kitano Y; Koyama J
ESC Heart Fail; 2021 Aug; 8(4):2647-2659. PubMed ID: 34137515
[TBL] [Abstract][Full Text] [Related]
39. First Norwegian case of hereditary ATTR amyloidosis with a novel transthyretin variant.
Lyng CS; Gude E; Hodt A; Knudsen EC
Scand Cardiovasc J; 2023 Dec; 57(1):2174269. PubMed ID: 36734834
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
